Form D · Pharmaceuticals
Arvinas, Inc.
New Haven, CT · CIK 0001581331
Offering snapshot reported Jul 16, 2013 · SEC filing
- Reported sold
- $3.51M Offering amount: $15.1M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 8, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 16, 2013 | Initial | $3,511,667 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-199736
Source: Form D, filed Jul 16, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Craig Crews | Promoter |
| Kush Parmar | Director |
| Tim Shannon | Director, Executive |
| Jonathan Soderstrom | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
5 Science Park 395 Winchester Avenue
New Haven, CT, 06511
New Haven, CT, 06511